Phathom Pharmaceuticals, Inc.
PHAT
$4.36
$0.215.06%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 6.43% | -97.90% | -123.23% | -119.10% | -44.55% |
| Total Depreciation and Amortization | 4.32% | 57.85% | 60.16% | 46.58% | 10.12% |
| Total Amortization of Deferred Charges | 11.13% | -36.16% | 172.16% | -4.44% | 13.88% |
| Total Other Non-Cash Items | -44.07% | 53.56% | 46.44% | 45.68% | 154.83% |
| Change in Net Operating Assets | -1,436.69% | 157.42% | -114.13% | 57.03% | 593.43% |
| Cash from Operations | -44.89% | -99.20% | -218.56% | -73.99% | -6.72% |
| Capital Expenditure | 98.95% | 95.31% | -666.67% | 81.31% | -15.29% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 98.95% | 95.31% | -666.67% | 81.31% | -15.29% |
| Total Debt Issued | -88.33% | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 938,800.00% | -99.99% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -87.71% | 938,800.00% | -82.49% | -29.65% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -122.31% | 277.95% | -138.56% | -129.20% | 504.61% |